Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Status:
RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).

PHASE2

University Health Network, Toronto

glofitamab